Literature DB >> 26006722

Dopamine-Responsive Growth-Hormone Deficiency and Central Hypothyroidism in Sepiapterin Reductase Deficiency.

Matthias Zielonka1, Nawal Makhseed2, Nenad Blau3, Markus Bettendorf4, Georg Friedrich Hoffmann3, Thomas Opladen5.   

Abstract

Sepiapterin reductase (SR) deficiency is a rare autosomal recessively inherited error of tetrahydrobiopterin (BH4) biosynthesis, resulting in disturbed dopaminergic and serotonergic neurotransmission. The clinical phenotype is characterized by dopa-responsive movement disorders including muscular hypotonia, dystonia, and parkinsonism. Due to the rarity of the disease, the phenotype of SR deficiency is far from being completely understood. Here, we report a 7-year-old boy, who was referred for diagnostic evaluation of combined psychomotor retardation, spastic tetraplegia, extrapyramidal symptoms, and short stature. Due to discrepancy between motor status and mental condition, analyses of biogenic amines and pterins in CSF were performed, leading to the diagnosis of SR deficiency. The diagnosis was confirmed by a novel homozygous mutation c.530G>C; p.(Arg177Pro) in exon 2 of the SPR gene. Because of persistent short stature, systematic endocrinological investigations were initiated. Insufficient growth-hormone release in a severe hypoglycemic episode after overnight fasting confirmed growth-hormone deficiency as a cause of short stature. In addition, central hypothyroidism was present. A general hypothalamic affection could be excluded. Since dopamine is known to regulate growth-hormone excretion, IGF-1, IGF-BP3, and peripheral thyroid hormone levels were monitored under L-dopa/carbidopa supplementation. Both growth-hormone-dependent factors and thyroid function normalized under treatment. This is the first report describing growth-hormone deficiency and central hypothyroidism in SR deficiency. It extends the phenotypic spectrum of the disease and identifies dopamine depletion as cause for the endocrinological disturbances.

Entities:  

Keywords:  Dopamine depletion; Hypoglycemia; Mental retardation; Parkinsonism; Sepiapterin reductase deficiency

Year:  2015        PMID: 26006722      PMCID: PMC4582026          DOI: 10.1007/8904_2015_450

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  25 in total

Review 1.  Neurochemistry and defects of biogenic amine neurotransmitter metabolism.

Authors:  K Hyland
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

2.  Disruption of the D2 dopamine receptor alters GH and IGF-I secretion and causes dwarfism in male mice.

Authors:  G Díaz-Torga; C Feierstein; C Libertun; D Gelman; M A Kelly; M J Low; M Rubinstein; D Becú-Villalobos
Journal:  Endocrinology       Date:  2002-04       Impact factor: 4.736

3.  Child neurology: paroxysmal stiffening, upward gaze, and hypotonia: hallmarks of sepiapterin reductase deficiency.

Authors:  P Dill; M Wagner; A Somerville; B Thöny; N Blau; P Weber
Journal:  Neurology       Date:  2012-01-31       Impact factor: 9.910

4.  Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder.

Authors:  B G R Neville; R Parascandalo; R Farrugia; A Felice
Journal:  Brain       Date:  2005-07-27       Impact factor: 13.501

5.  Dopamine stimulates release of thyrotrophin-releasing hormone from perfused intact rat hypothalamus via hypothalamic D2-receptors.

Authors:  B M Lewis; C Dieguez; M D Lewis; M F Scanlon
Journal:  J Endocrinol       Date:  1987-12       Impact factor: 4.286

Review 6.  Inborn errors of neurotransmitter receptors.

Authors:  R Surtees
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

7.  A murine model for human sepiapterin-reductase deficiency.

Authors:  Seungkyoung Yang; Young Jae Lee; Jin-Man Kim; Sean Park; Joanna Peris; Philip Laipis; Young Shik Park; Jae Hoon Chung; S Paul Oh
Journal:  Am J Hum Genet       Date:  2006-01-31       Impact factor: 11.025

8.  Aromatic L-amino acid decarboxylase deficiency is a cause of long-fasting hypoglycemia.

Authors:  Jean-Baptiste Arnoux; Léna Damaj; Sylvia Napuri; Valérie Serre; Laurence Hubert; Marylène Cadoudal; Gilles Simard; Irène Ceballos; Laurence Christa; Pascale de Lonlay
Journal:  J Clin Endocrinol Metab       Date:  2013-09-13       Impact factor: 5.958

Review 9.  Pediatric neurotransmitter diseases.

Authors:  Phillip L Pearl; Denise D Wallis; K Michael Gibson
Journal:  Curr Neurol Neurosci Rep       Date:  2004-03       Impact factor: 5.081

10.  Levodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian rats.

Authors:  Ippolita Cantuti-Castelvetri; Ledia F Hernandez; Christine E Keller-McGandy; Lauren R Kett; Alex Landy; Zane R Hollingsworth; Esen Saka; Jill R Crittenden; Eduardo A Nillni; Anne B Young; David G Standaert; Ann M Graybiel
Journal:  PLoS One       Date:  2010-11-10       Impact factor: 3.240

View more
  3 in total

Review 1.  Combining Human and Rodent Genetics to Identify New Analgesics.

Authors:  Alban Latremoliere; Michael Costigan
Journal:  Neurosci Bull       Date:  2017-07-01       Impact factor: 5.203

Review 2.  Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies.

Authors:  Thomas Opladen; Eduardo López-Laso; Elisenda Cortès-Saladelafont; Toni S Pearson; H Serap Sivri; Yilmaz Yildiz; Birgit Assmann; Manju A Kurian; Vincenzo Leuzzi; Simon Heales; Simon Pope; Francesco Porta; Angeles García-Cazorla; Tomáš Honzík; Roser Pons; Luc Regal; Helly Goez; Rafael Artuch; Georg F Hoffmann; Gabriella Horvath; Beat Thöny; Sabine Scholl-Bürgi; Alberto Burlina; Marcel M Verbeek; Mario Mastrangelo; Jennifer Friedman; Tessa Wassenberg; Kathrin Jeltsch; Jan Kulhánek; Oya Kuseyri Hübschmann
Journal:  Orphanet J Rare Dis       Date:  2020-05-26       Impact factor: 4.123

Review 3.  Sepiapterin reductase: Characteristics and role in diseases.

Authors:  Yao Wu; Peng Chen; Li Sun; Shengtao Yuan; Zujue Cheng; Ligong Lu; Hongzhi Du; Meixiao Zhan
Journal:  J Cell Mol Med       Date:  2020-07-30       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.